Lipoxins as biomarkers of lupus and other inflammatory conditions
<p>Abstract</p> <p>Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so tissue/organ damage continues. The contin...
Main Author: | Das Undurti N |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-05-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://www.lipidworld.com/content/10/1/76 |
Similar Items
-
Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection
by: Anandita Pal, et al.
Published: (2020-08-01) -
The Role of Eicosanoids in Alzheimer’s Disease
by: Roger G. Biringer
Published: (2019-07-01) -
Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation
by: Charles N Serhan, et al.
Published: (2012-10-01) -
The Anti-Inflammatory Role of Omega-3 Polyunsaturated Fatty Acids Metabolites in Pre-Clinical Models of Psychiatric, Neurodegenerative, and Neurological Disorders
by: Juliette Giacobbe, et al.
Published: (2020-02-01) -
Omega 3 Fatty Acid and Skin Diseases
by: Yu Sawada, et al.
Published: (2021-02-01)